Adrian R. Krainer

Cold Spring Harbor Laboratory — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

100h-index36.6kcitations249works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Research and Splicing(189), RNA modifications and cancer(118), RNA and protein synthesis mechanisms(114), Neurogenetic and Muscular Disorders Research(40), RNA Interference and Gene Delivery(28)

Publications249 total

MYC-Driven Activation of USP39 Enhances SRSF1 Stability and Promotes PDAC Progression
2025Open Access
180: AMMONIA-MEDIATED DISRUPTION OF TGF-B SIGNALING IN EARLY-ONSET COLORECTAL CANCER
Gastroenterology·2025
Abstract 6533: Microbial metabolite ammonia disrupts CEACAM1 TGF-β signaling to drive colon cancer progression
Cancer Research·2025
Su1127 MYOSTATIN CONTRIBUTES TO ALTERATIONS IN METABOLIC PATHWAYS AND MUSCLE ATROPHY IN MASH AND HCC AND IS A PROMISING BIOMARKER WITH METABOLIC MARKER PKM2 FOR RISK STRATIFICATION OF HCC
Gastroenterology·2024
Abstract 771: A TGF-β superfamily member, myostatin contributes to MASH and HCC via muscle atrophy by disrupting TGF-β signaling, and is a potential marker with PKM2 for human HCC
Cancer Research·2024
Opportunities and challenges for innovative and equitable healthcare
Nature Reviews Drug Discovery·2024· 8 cited
Preclinical Screening of Splice-Switching Antisense Oligonucleotides in PDAC Organoids
2023· 1 citedOpen Access
Data from ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth
2023Open Access
Supplementary Data from ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth
2023Open Access
Supplementary Table from ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth
2023Open Access
Supplementary Table from ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth
2023Open Access
Supplementary Data from ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth
2023Open Access
Data from ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth
2023Open Access
RNA therapeutics
RNA·2023· 24 citedOpen Access
Specificity, cooperativity, synergy, and mechanisms of splice-modifying drugs
Biophysical Journal·2023· 2 citedOpen Access
Specificity, synergy, and mechanisms of splice-modifying drugs
2022· 9 citedOpen Access
Author Correction: Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia
Nature Communications·2021· 1 citedOpen Access
Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia
Nature Communications·2021· 41 citedOpen Access
Evidence generation and reproducibility in cell and gene therapy research: A call to action
Molecular Therapy — Methods & Clinical Development·2021· 22 citedOpen Access
Identification of SRSF10 as a regulator of <i>SMN2</i> ISS‐N1
Human Mutation·2020· 18 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Yimin Hua(8), C. Frank Bennett(7), Luca Cartegni(6), Akila Mayeda(6), Javier F. Cáceres(5), Michael Q. Zhang(5), Tom Maniatis(4), Frank Rigo(4), Gene Hung(4), Shern L. Chew(3), Chaolin Zhang(3), Michelle L. Hastings(3), Zuo‐Feng Zhang(3), Rotem Karni(2), Elisa de Stanchina(2), Barbara Ruskin(2), Michael R. Green(2), Kentaro Sahashi(2), Marco A. Passini(2), Timothy A. Vickers(2)